Dibenzothiophene

Dibenzothiophene is an orally active and a noncompetitive CYP1A inhibitor. Dibenzothiophene inhibits CYP1A-mediated EROD activity with a Km of 0.592 μM. Dibenzothiophene interacts with the AHR pathway. Dibenzothiophene enhances the embryotoxicity of β-naphthoflavone (HY-114740) . Dibenzothiophene shows acute toxicity in mice. Dibenzothiophene is mainly used for the study of the mechanism of developmental toxicity in organisms[1][2].

Product Specifications

CAS Number

[132-65-0]

Product Name Alternative

DBT; Diphenylene sulfide

UNSPSC

12352005

Hazard Statement

H302, H410

Target

Aryl Hydrocarbon Receptor; Cytochrome P450

Type

Reference compound

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Dibenzothiophene.html

Purity

99.98

Solubility

DMSO : 75 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

C12=CC=CC=C1C3=CC=CC=C3S2

Molecular Formula

C12H8S

Molecular Weight

184.26

Precautions

H302, H410

References & Citations

[1]Wassenberg DM, et al. Effects of the polycyclic aromatic hydrocarbon heterocycles, carbazole and dibenzothiophene, on in vivo and in vitro CYP1A activity and polycyclic aromatic hydrocarbon-derived embryonic deformities. Environ Toxicol Chem. 2005 Oct;24 (10) :2526-32. |[2]Leighton FA. Acute oral toxicity of dibenzothiophene for male CD-1 mice: LD50, lesions, and the effect of preinduction of mixed-function oxidases. Fundam Appl Toxicol. 1989 May;12 (4) :787-92.